Siemens Healthineers AG
Siemens Healthineers AG (SEMHF) Financial Performance & Income Statement Overview
Review Siemens Healthineers AG (SEMHF) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Siemens Healthineers AG (SEMHF) Income Statement & Financial Overview
Explore comprehensive income reports for Siemens Healthineers AG SEMHF, broken down by year and quarter.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $5.91B | $5.48B | $6.33B | $5.42B |
| Cost of Revenue | $3.59B | $3.33B | $3.92B | $3.33B |
| Gross Profit | $2.32B | $2.15B | $2.41B | $2.09B |
| Gross Profit Ratio | $0.39 | $0.39 | $0.38 | $0.39 |
| R&D Expenses | $485.00M | $481.00M | $496.00M | $484.00M |
| SG&A Expenses | $991.00M | $973.00M | $962.00M | $918.00M |
| Operating Expenses | $1.48B | $1.46B | $1.46B | $1.40B |
| Total Costs & Expenses | $5.07B | $4.79B | $5.38B | $4.74B |
| Interest Income | $25.00M | $31.00M | $29.00M | $27.00M |
| Interest Expense | $104.00M | $108.00M | $142.00M | $116.00M |
| Depreciation & Amortization | $312.00M | $305.00M | $309.00M | $295.00M |
| EBITDA | $1.15B | $1.03B | $1.29B | $1.006B |
| EBITDA Ratio | $0.19 | $0.19 | $0.20 | $0.19 |
| Operating Income | $844.00M | $697.00M | $950.00M | $688.00M |
| Operating Income Ratio | $0.14 | $0.13 | $0.15 | $0.13 |
| Other Income/Expenses (Net) | -$114.00M | -$80.00M | -$106.00M | -$93.00M |
| Income Before Tax | $730.00M | $617.00M | $844.00M | $595.00M |
| Income Before Tax Ratio | $0.12 | $0.11 | $0.13 | $0.11 |
| Income Tax Expense | $194.00M | $138.00M | $221.00M | $123.00M |
| Net Income | $530.00M | $474.00M | $616.00M | $469.00M |
| Net Income Ratio | $0.09 | $0.09 | $0.10 | $0.09 |
| EPS | $0.47 | $0.42 | $0.55 | $0.42 |
| Diluted EPS | $0.47 | $0.42 | $0.55 | $0.42 |
| Weighted Avg Shares Outstanding | $1.13B | $1.13B | $1.12B | $1.12B |
| Weighted Avg Shares Outstanding (Diluted) | $1.13B | $1.13B | $1.12B | $1.12B |
The company's financials show resilient growth, with revenue advancing from $5.42B in Q3 2024 to $5.91B in Q2 2025. Gross profit remained healthy with margins at 39% in Q2 2025 compared to 39% in Q3 2024. Operating income hit $844.00M last quarter, sustaining a consistent 14% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $1.15B. Net income rose to $530.00M, while earnings per share reached $0.47. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan